Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy & School of Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China.
School Infirmary, Jiangsu Normal University, Xuzhou, Jiangsu 221132, China.
J Diabetes Res. 2022 Mar 18;2022:4491900. doi: 10.1155/2022/4491900. eCollection 2022.
The present study is aimed at exploring the effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on weight in type 2 diabetes mellitus (T2DM) and therapeutic regimen recommendations.
20,019 patients with T2DM were enrolled. The maximal effect ( ) models, whose evaluation index was change rate of body weight from baseline value, were used to analyze data using nonlinear mixed effect modeling (NONMEM).
For SGLT-2 inhibitors, canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin and tofogliflozin, the , and treatment duration to reach half of the maximal effects (ET) were -3.72% and 3.35 weeks, -5.59% and 16.8 weeks, -2.84% and 3.42 weeks, -3.43% and 3.09 weeks, -3.04% and 4.38 weeks, and -2.45% and 3.16 weeks, respectively. In addition, for T2DM patients, 100 mg/day canagliflozin needs to be taken 13.4 weeks for the plateau of effect on weight; 10 mg/day empagliflozin needs to be taken 67.2 weeks for the plateau of effect on weight; 5 mg/day ertugliflozin needs to be taken 13.68 weeks for the plateau of effect on weight; 50 mg/day ipragliflozin needs to be taken 12.36 weeks for the plateau of effect on weight; 2.5 mg/day luseogliflozin needs to be taken 17.52 weeks for the plateau of effect on weight; 20 mg/day tofogliflozin needs to be taken 12.64 weeks for the plateau of effect on weight.
This was the first study to explore effects of SGLT-2 inhibitors on weight in T2DM; meanwhile, the optimum dosages and treatment durations on weight from canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, and tofogliflozin were recommended, respectively.
本研究旨在探讨钠-葡萄糖共转运蛋白 2（SGLT-2）抑制剂对 2 型糖尿病（T2DM）患者体重的影响，并提出治疗方案建议。
纳入 20019 例 T2DM 患者。采用最大效应（）模型，以体重从基线值的变化率为评价指标，通过非线性混合效应模型（NONMEM）进行数据分析。
对于 SGLT-2 抑制剂，卡格列净、恩格列净、埃格列净、伊格列净、鲁格列净和托格列净，、半最大效应（ET）达到时间（）分别为-3.72%和 3.35 周、-5.59%和 16.8 周、-2.84%和 3.42 周、-3.43%和 3.09 周、-3.04%和 4.38 周、-2.45%和 3.16 周。此外，对于 T2DM 患者，100mg/d 卡格列净需要 13.4 周达到体重的效应平台；10mg/d 恩格列净需要 67.2 周达到体重的效应平台；5mg/d 埃格列净需要 13.68 周达到体重的效应平台；50mg/d 伊格列净需要 12.36 周达到体重的效应平台；2.5mg/d 鲁格列净需要 17.52 周达到体重的效应平台；20mg/d 托格列净需要 12.64 周达到体重的效应平台。
这是首次研究 SGLT-2 抑制剂对 T2DM 患者体重的影响，同时推荐了卡格列净、恩格列净、埃格列净、伊格列净、鲁格列净和托格列净的最佳剂量和治疗时间。
